ARDX - Ardelyx Inc
Ardelyx Inc Logo

ARDX - Ardelyx Inc

https://www.ardelyx.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.

52W High
$7.18
52W Low
$3.21
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.73
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-27.36
EV/Revenue (<3 favorable)
3.99
P/S (TTM) (<3 favorable)
4.07
P/B (<3 favorable)
11.26
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
2.45%
Institutions (25–75% balanced)
70.88%
Shares Outstanding
240,983,000
Float
232,645,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
386,146,000
Gross Profit (TTM)
273,392,000
EPS (TTM)
-0.24
Profit Margin (>10% good)
-0.15%
Operating Margin (TTM) (higher better)
-0.15%
ROE (TTM) (>15% strong)
-0.39%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.33
Momentum
Bearish momentum
Value
0.4389
Previous
0.4601
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025